Prevention of vaginal and rectal HIV transmission by antiretroviral combinations in humanized mice

Philippe A. Gallay, Udayan Chatterji, Aaron Kirchhoff, Angel Gandarilla, Manjula Gunawardana, Richard Pyles, Mark A. Marzinke, John A. Moss, Marc M. Baum

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

With more than 7,000 new HIV infections daily worldwide, there is an urgent need for non-vaccine biomedical prevention (nBP) strategies that are safe, effective, and acceptable. Clinical trials have demonstrated that pre-exposure prophylaxis (PrEP) with antiretrovirals (ARVs) can be effective at preventing HIV infection. In contrast, other trials using the same ARVs failed to show consistent efficacy. Topical (vaginal and rectal) dosing is a promising regimen for HIV PrEP as it leads to low systematic drug exposure. A series of titration studies were carried out in bone marrow/liver/thymus (BLT) mice aimed at determining the adequate drug concentrations applied vaginally or rectally that offer protection against rectal or vaginal HIV challenge. The dose-response relationship of these agents was measured and showed that topical tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) can offer 100% protection against rectal or vaginal HIV challenges. From the challenge data, EC50 values of 4.6 μM for TDF and 0.6 μM for FTC for HIV vaginal administration and 6.1 μM TDF and 0.18 μM for FTC for rectal administration were obtained. These findings suggest that the BLT mouse model is highly suitable for studying the dose-response relationship in single and combination ARV studies of vaginal or rectal HIV exposure. Application of this sensitive HIV infection model to more complex binary and ternary ARV combinations, particularly where agents have different mechanisms of action, should allow selection of optimal ARV combinations to be advanced into pre-clinical and clinical development as nBP products.

Original languageEnglish (US)
Article numbere0184303
JournalPLoS One
Volume12
Issue number9
DOIs
StatePublished - Sep 1 2017

Fingerprint

Tenofovir
HIV infections
Thymus
HIV
Liver
bone marrow
dose response
mice
disease control
Bone
HIV Infections
drugs
liver
Thymus Gland
titration
Titration
Pharmaceutical Preparations
Bone Marrow
Intravaginal Administration
clinical trials

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Gallay, P. A., Chatterji, U., Kirchhoff, A., Gandarilla, A., Gunawardana, M., Pyles, R., ... Baum, M. M. (2017). Prevention of vaginal and rectal HIV transmission by antiretroviral combinations in humanized mice. PLoS One, 12(9), [e0184303]. https://doi.org/10.1371/journal.pone.0184303

Prevention of vaginal and rectal HIV transmission by antiretroviral combinations in humanized mice. / Gallay, Philippe A.; Chatterji, Udayan; Kirchhoff, Aaron; Gandarilla, Angel; Gunawardana, Manjula; Pyles, Richard; Marzinke, Mark A.; Moss, John A.; Baum, Marc M.

In: PLoS One, Vol. 12, No. 9, e0184303, 01.09.2017.

Research output: Contribution to journalArticle

Gallay, PA, Chatterji, U, Kirchhoff, A, Gandarilla, A, Gunawardana, M, Pyles, R, Marzinke, MA, Moss, JA & Baum, MM 2017, 'Prevention of vaginal and rectal HIV transmission by antiretroviral combinations in humanized mice', PLoS One, vol. 12, no. 9, e0184303. https://doi.org/10.1371/journal.pone.0184303
Gallay, Philippe A. ; Chatterji, Udayan ; Kirchhoff, Aaron ; Gandarilla, Angel ; Gunawardana, Manjula ; Pyles, Richard ; Marzinke, Mark A. ; Moss, John A. ; Baum, Marc M. / Prevention of vaginal and rectal HIV transmission by antiretroviral combinations in humanized mice. In: PLoS One. 2017 ; Vol. 12, No. 9.
@article{205b5f541386456d8fe98ffdb02f7548,
title = "Prevention of vaginal and rectal HIV transmission by antiretroviral combinations in humanized mice",
abstract = "With more than 7,000 new HIV infections daily worldwide, there is an urgent need for non-vaccine biomedical prevention (nBP) strategies that are safe, effective, and acceptable. Clinical trials have demonstrated that pre-exposure prophylaxis (PrEP) with antiretrovirals (ARVs) can be effective at preventing HIV infection. In contrast, other trials using the same ARVs failed to show consistent efficacy. Topical (vaginal and rectal) dosing is a promising regimen for HIV PrEP as it leads to low systematic drug exposure. A series of titration studies were carried out in bone marrow/liver/thymus (BLT) mice aimed at determining the adequate drug concentrations applied vaginally or rectally that offer protection against rectal or vaginal HIV challenge. The dose-response relationship of these agents was measured and showed that topical tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) can offer 100{\%} protection against rectal or vaginal HIV challenges. From the challenge data, EC50 values of 4.6 μM for TDF and 0.6 μM for FTC for HIV vaginal administration and 6.1 μM TDF and 0.18 μM for FTC for rectal administration were obtained. These findings suggest that the BLT mouse model is highly suitable for studying the dose-response relationship in single and combination ARV studies of vaginal or rectal HIV exposure. Application of this sensitive HIV infection model to more complex binary and ternary ARV combinations, particularly where agents have different mechanisms of action, should allow selection of optimal ARV combinations to be advanced into pre-clinical and clinical development as nBP products.",
author = "Gallay, {Philippe A.} and Udayan Chatterji and Aaron Kirchhoff and Angel Gandarilla and Manjula Gunawardana and Richard Pyles and Marzinke, {Mark A.} and Moss, {John A.} and Baum, {Marc M.}",
year = "2017",
month = "9",
day = "1",
doi = "10.1371/journal.pone.0184303",
language = "English (US)",
volume = "12",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "9",

}

TY - JOUR

T1 - Prevention of vaginal and rectal HIV transmission by antiretroviral combinations in humanized mice

AU - Gallay, Philippe A.

AU - Chatterji, Udayan

AU - Kirchhoff, Aaron

AU - Gandarilla, Angel

AU - Gunawardana, Manjula

AU - Pyles, Richard

AU - Marzinke, Mark A.

AU - Moss, John A.

AU - Baum, Marc M.

PY - 2017/9/1

Y1 - 2017/9/1

N2 - With more than 7,000 new HIV infections daily worldwide, there is an urgent need for non-vaccine biomedical prevention (nBP) strategies that are safe, effective, and acceptable. Clinical trials have demonstrated that pre-exposure prophylaxis (PrEP) with antiretrovirals (ARVs) can be effective at preventing HIV infection. In contrast, other trials using the same ARVs failed to show consistent efficacy. Topical (vaginal and rectal) dosing is a promising regimen for HIV PrEP as it leads to low systematic drug exposure. A series of titration studies were carried out in bone marrow/liver/thymus (BLT) mice aimed at determining the adequate drug concentrations applied vaginally or rectally that offer protection against rectal or vaginal HIV challenge. The dose-response relationship of these agents was measured and showed that topical tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) can offer 100% protection against rectal or vaginal HIV challenges. From the challenge data, EC50 values of 4.6 μM for TDF and 0.6 μM for FTC for HIV vaginal administration and 6.1 μM TDF and 0.18 μM for FTC for rectal administration were obtained. These findings suggest that the BLT mouse model is highly suitable for studying the dose-response relationship in single and combination ARV studies of vaginal or rectal HIV exposure. Application of this sensitive HIV infection model to more complex binary and ternary ARV combinations, particularly where agents have different mechanisms of action, should allow selection of optimal ARV combinations to be advanced into pre-clinical and clinical development as nBP products.

AB - With more than 7,000 new HIV infections daily worldwide, there is an urgent need for non-vaccine biomedical prevention (nBP) strategies that are safe, effective, and acceptable. Clinical trials have demonstrated that pre-exposure prophylaxis (PrEP) with antiretrovirals (ARVs) can be effective at preventing HIV infection. In contrast, other trials using the same ARVs failed to show consistent efficacy. Topical (vaginal and rectal) dosing is a promising regimen for HIV PrEP as it leads to low systematic drug exposure. A series of titration studies were carried out in bone marrow/liver/thymus (BLT) mice aimed at determining the adequate drug concentrations applied vaginally or rectally that offer protection against rectal or vaginal HIV challenge. The dose-response relationship of these agents was measured and showed that topical tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) can offer 100% protection against rectal or vaginal HIV challenges. From the challenge data, EC50 values of 4.6 μM for TDF and 0.6 μM for FTC for HIV vaginal administration and 6.1 μM TDF and 0.18 μM for FTC for rectal administration were obtained. These findings suggest that the BLT mouse model is highly suitable for studying the dose-response relationship in single and combination ARV studies of vaginal or rectal HIV exposure. Application of this sensitive HIV infection model to more complex binary and ternary ARV combinations, particularly where agents have different mechanisms of action, should allow selection of optimal ARV combinations to be advanced into pre-clinical and clinical development as nBP products.

UR - http://www.scopus.com/inward/record.url?scp=85029883427&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029883427&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0184303

DO - 10.1371/journal.pone.0184303

M3 - Article

VL - 12

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 9

M1 - e0184303

ER -